孙永存,拉周措毛

低氧性肺动脉高压（hypoxic pulmonary hypertension，HPH）是一种严重的慢性心肺疾病，其特征是肺血管阻力增加，最终导致右心室功能衰竭。HPH常见于高原居民、慢性肺部疾病患者及先天性心脏病患者中。近年来，随着对HPH发病机制的深入研究，药物治疗策略也在不断发展。本文将从HPH的发病机制和药物治疗两个方面，总结当前的研究进展，并探讨未来的研究方向。

低氧性肺动脉高压；血管重构；发病机制；药物治疗

[1] HOEPER M M,HUMBERT M,SOUZA R,et al.A global view of pulmonary hypertension[J].Lancet Respir Med,2016,4(4):306-22. [2] GALIèN,HUMBERT M,VACHIERY J L,et al.2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension [J].Rev Esp Cardiol(Engl Ed),2016,69(2):177. [3] MOCUMBI A,HUMBERT M,SAXENA A,et al.Pulmonary hypertension[J].Nat Rev Dis Primers,2024,10(1):1. [4] MIRRAKHIMOV A E,STROHL K P.High-altitude Pulmonary Hypertension:an Update on Disease Pathogenesis and Management[J]. Open Cardiovasc Med J,2016,10:19-27. [5] DENG Z H,CHEN Y X,XUE G,et al.Mesenchymal stem cell-derived exosomes ameliorate hypoxic pulmonary hypertension by inhibiting the Hsp90aa1/ERK/pERK pathway[J].Biochem Pharmacol,2024,226:116382. [6] WANG R,PAN J,WANG D,et al.“Blue lips”:research progress in pulmonary vascular remodeling in hypoxic pulmonary hypertension[J]. SCIENTIA SINICA Vitae,2021,51(12):1637-45. [7] CHAI T,QIU C,XIAN Z,et al.A narrative review of research advances in hypoxic pulmonary hypertension[J].Annals of Translational Medicine,2022,10(4):230. [8] 杨智伟,赵施皓,郑煦暘,等.钙敏感受体参与低氧性肺动脉高压形成的研究进展[J].心脏杂志,2013,25(04):490-3. [9] XU D,HU Y-H,GOU X,et al.Oxidative Stress and Antioxidative Therapy in Pulmonary Arterial Hypertension[J].Molecules, 2022,27(12):3724. [10] THENAPPAN T,ORMISTON M L,RYAN J J,et al.Pulmonary arterial hypertension:pathogenesis and clinical management[J].BMJ, 2018,360:j5492. [11] 王建美,袁天翊,高丽,等.低氧性肺动脉高压病理机制与治疗药物研究进展[J].中国药理学通报,2022,38(09):1281-8. [12] JAITOVICH A,JOURD'HEUIL D.A Brief Overview of Nitric Oxide and Reactive Oxygen Species Signaling in Hypoxia-Induced Pulmonary Hypertension[J].Adv Exp Med Biol,2017,967:71-81. [13] 徐康乔,夏世金.低氧性肺动脉高压发生机制与诊治新策略[J].中华肺部疾病杂志(电子版),2020,13(02):127-33. [14] 丁兴,孙莉,王苒.低氧性肺动脉高压发病机制研究进展[J].临床肺科杂志,2017,22(07):1318-9+22. [15] VELAYATI A,VALERIO M G,SHEN M,et al.Update on pulmonary arterial hypertension pharmacotherapy[J].Postgrad Med,2016, 128(5):460-73. [16] HE X,SONG S,AYON R J,et al.Hypoxia selectively upregulates cation channels and increases cytosolic[Ca(2+)]in pulmonary,but not coronary,arterial smooth muscle cells[J].Am J Physiol Cell Physiol,2018,314(4):C504-c17. [17] LIU J,WANG W,WANG L,et al.IL-33 Initiates Vascular Remodelling in Hypoxic Pulmonary Hypertension by up-Regulating HIF-1αand VEGF Expression in Vascular Endothelial Cells[J].EBioMedicine,2018,33:196-210. [18] SHARMIN N,NGANWUCHU C C,NASIM M T.Targeting the TGF-βsignaling pathway for resolution of pulmonary arterial hypertension[J].Trends Pharmacol Sci,2021,42(7):510-3. [19] 杨利萍,张友兰,唐凤鸣,等.基于TGFβ1/Smad7通路观察麻黄碱对肺心病大鼠血管内皮结构及功能的影响[J].西部中医药, 2022,35(04):48-54. [20] YE J X,WANG S S,GE M,et al.Suppression of endothelial PGC-1αis associated with hypoxia-induced endothelial dysfunction and provides a new therapeutic target in pulmonary arterial hypertension[J].Am J Physiol Lung Cell Mol Physiol,2016,310(11):L1233-42. [21] 王玉香,马兰.低氧诱导肺动脉高压肺血管内皮-间充质转化作用机制的研究进展[J].中国病理生理杂志,2025,41(04):804-8. [22] HE Y U,ZONG-AN L.Progress in medication of pulmonary hypertension[J].Modern Preventive Medicine,2012. [23] ALI K,HOSSAM K,AHMED A,et al.Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension[J].Expert Opinion on Drug Delivery,2020,17(4):439-61. [24] RUI W,MENG W,JIE W,et al.A Network Meta-analysis of the Efficacy and Safety of Targeted Drug Combinations in the Treatment of Pulmonary Arterial Hypertension[J].Cardiology Discovery,2023. [25] YONGJING Z,SHILING H,SHUAI G,et al.Paeoniflorin inhibits IgE-mediated allergic reactions by suppressing the degranulation of mast cells though binding with FcϵRI alpha subunits[J].European Journal of Pharmacology,2020,886:173415. [26] 王贞丽,姜萍,李丙华,等.芍药苷对大鼠低氧性肺动脉高压的防治作用及其抗氧化机制研究[J].中国海洋药物,2022,41(04):51-8. [27] MUSASHAYKHOVA S A,TRUKHIN D I,VALIEVA Z S,et al.Soluble guanylate cyclase stimulator riociguat in the palette of modern specific therapy for precapillary pulmonary hypertension:from the pathophysiological basis to the results of current research[J].Systemic Hypertension,2023,19(4):45-52. [28] JIN-JING Z,UNDEFINED M-M,MIN-MIN S,et al.Therapeutic potential of natural flavonoids in pulmonary arterial hypertension:A review[J].Phytomedicine,2024,128:155535.

点击下载PDF